Role of skeletal muscle in thiazolidinedione insulin sensitizer (PPARγ agonist) action

Endocrinology

Volumn 139, Issue 12, 1998, Pages 5034-5041

  Zierath, Juleen R ^a   Ryder, Jeffrey W ^a   Doebber, Thomas ^b   Woods, John ^b   Wu, Margaret ^b   Ventre, John ^b   Li, Zhihua ^b   Mccrary, Christine ^b   Berger, Joel ^b   Zhang, Bei ^b   Moller, David E ^b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; DEOXYGLUCOSE; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; ROSIGLITAZONE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; GASTROCNEMIUS MUSCLE; GLUCOSE UTILIZATION; HEART MUSCLE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID METABOLISM; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR UPREGULATION; SOLEUS MUSCLE;

EID: 7844240131     PISSN: 00137227     EISSN: None     Source Type: Journal    
DOI: 10.1210/endo.139.12.6364     Document Type: Article

References (43)

1. Whitcomb RW, Saltiel AR, Lockwood DH 1996 New therapies for non-insulin-dependent diabetes mellitus: thiazolidinediones. In: LeRoith D, Taylor SI, Olefsky JM (eds) Diabetes Mellitus. Lippincott-Raven, Philadelphia, pp 661-668
2. Bowen L, Stein PP, Stevenson R, Shulman GI 1991 The effect of CP 68,722, a thiazolidinedione derivative, on insulin sensitivity in lean and obese Zucker rats. Metabolism 40:1025-1030
3. Berger J, Bailey P, Biswas C, Cullinan CA, Doebber TW, Hayes NS, Saperstein R, Smith RG, Leibowitz MD 1996 Thiazolidinediones produce a conformational change in peroxisomal proliferator-activated receptor-γ: binding and activation correlate with antidiabetic actions in db / db mice. Endocrinology 137:4189-4195
4. Fujiwara T, Yoshioka S, Yoshioka T, Ushiyama I, Horikoshi H 1988 Characterization of new oral antidiabetic agent CS-045. Studies in KK and ob / ob mice and Zucker fatty rats. Diabetes 37:1549-1558
5. Young PW, Cawthorne MA, Coyle PJ, Holder JC, Holman GD, Kozka IJ, Kirkham DM, Lister CA, Smith SA 1995 Repeat treatment of obese mice with BRL 49653, a new and potent insulin sensitizer, enhances insulin action in white adipocytes. Diabetes 44:1087-1092
6. Wasada T, Omori Y, Sasaki H, Kawamori R, Yamasaki Y, Baba S, Shichiri M, Kaneko T 1996 Effect of Pioglitazone (AD-4833) on insulin stimulated glucose disposal in NIDDM, an assessment by the euglycemic hyperinsulinemic clamp method. Diabetes [Suppl] 45:73A
7. Chaiken RL, Eckert-Norton M, Pasmantier R, Boden G, Ryan I, Gelfand RA, Lebovitz HE 1995 Metabolic effects of darglitazone, an insulin sensitizer, in NIDDM subjects. Diabetologia 38:1307-1312
8. Nolan JJ, Ludvik B, Beerdsen P, Joyce M, Olefsky J 1994 Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med 331:1188-1193
9. Kletzien RF, Clarke SD, Ulrich RG 1992 Enhancement of adipocyte differentiation by an insulin-sensitizing agent. Mol Pharmacol 41:393-398
10. Szalkowski D, White-Carrington S, Berger J, Zhang B 1995 Antidiabetic thiazolidinediones block the inhibitory effect of tumor necrosis factor-α on differentiation, insulin-stimulated glucose uptake, and gene expression in 3T3-L1 cells. Endocrinology 136:1474-1481
11. Tontonoz P, Hu E, Spiegelman BM 1995 Regulation of adipocyte gene expression and differentiation by peroxisome proliferator activated receptor γ. Curr Biol 5:571-576
12. Zhu Y, Qi C, Korenberg JR, Chen XN, Noya D, Sambasiva Rao M, Reddy JK 1995 Structural organization of mouse peroxisome proliferator-activated receptor γ (m PPAR γ) gene: alternative promoter use and different splicing yield two m PPAR y isoforms. Proc Natl Acad Sci USA 92:7921-7925
13. Tontonoz P, Hu E, Spiegelman BM 1994 Stimulation of adipogenesis in fibroblasts by PPAR γ 2, a lipid activated transcription factor. Cell 79:1147-1156
14. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA 1995 An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ. J Biol Chem 270:12953-12956
15. Willson TM, Cobb JE, Cowan DJ, Wiethe RW, Correa ID, Prakash SR, Beck KD, Moore LB, Kliewer SA, Lehmann JM 1996 The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones. J Med Chem 39:665-668
16. Berger J, Leibowitz MD, Doebber TW, Elbrecht A, Zhang B, Zhou G, Biswas C, Chen Y, Cullinan CA, Hayes NS, Li Z, Ventre J, Wu MS, Smith RG, Tolman R, Moller DE 1998 Novel PPARγ and PPARδ ligands possess distinct biological properties. In: Keystone Symposium on Nuclear Receptor Family. Incline Village, NV
17. Buckle DR, Cantello BCC, Cawthorne MA, Coyle PJ, Dean DK, Faller A, Haigh D, Hindley RM, Jefcott LJ, Lister CA, Pinto IL, Rami HK, Smith DG, Smith SA 1996 Non thiazolidinedione antihyperglycaemic agents. 1: a-heteroatom substituted b-phenylpropanoic acids. Bioorg Med Chem Ltrs 6:2121-2126
18. Mukerjee R, Davies PJA, Crombie DL, Bischoff ED, Cesario RM, Jow L, Hamann LG, Boehm MF, Mondon CE, Nadzan AM, Patemiti JR, Heyman RA 1997 Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists. Nature 386:407-410
19. Schoonjans K, Peinado-Onsurbe J, Lefebvre AM, Heyman RA, Briggs M, Deeb S, Staels B, Auwerx J 1996 PPARα and PPARγ activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J 15:5336-5348
20. Kraegen EW, James DE, Jenkins AB, Chisholm DJ 1985 Dose-response curves for in vivo insulin sensitivity in individual tissues in rats. Am J Physiol 248:E353-E362
21. DeFronzo RA, Jacot E, Jequier E, Maeder E, Wahren J, Felber JP 1981 The effect of insulin on the disposal of intravenous glucose: results from indirect calorimetry and hepatic and femoral venous catheterization. Diabetes 30:1000-1007
22. Vidal-Puig A, Jimenez-Linan M, Hamann A, Lowell BB, Hu E, Spiegelman BM, Flier JS, Moller DE 1996 Regulation of PPARγ gene expression in vivo by nutrition and obesity. J Clin Invest 97:2553-2561
23. Vidal-Puig AJ, Considine RV, Jimenez-Linan M, Werman A, Pories WJ, Caro JF, Flier JS 1997 Peroxisome proliferator-activated receptor gene expression in human tissues: effects of obesity, weight loss, and regulation by insulin and glucocorticoids. J Clin Invest 99:2416-2422
24. Park KS, Ciaraldi TP, Abrams-Carter L, Mudaliar S, Nikoulina SE, Henry RR 1997 PPAR-gamma gene expression is elevated in skeletal muscle of obese and type II diabetic subjects. Diabetes 46:1230-1234
25. Mukherjee R, Jow L, Croston GE, Patemiti JR 1997 Identification, characterization and tissue distribution of human peroxisome proliferator-activated receptor (PPAR) isoforms PPARgamma2 vs. PPARgammal and activation with retinoid X receptor agonists and antagonists. J Biol Chem 272:8071-8076
26. Elbrecht A, Chen Y, Cullinan CA, Hayes N, Leibowitz MD, Moller DE, Berger J 1996 Molecular cloning, expression and characterization of human peroxisome proliferator activated receptors gammal and gamma2. Biochem Biophys Res Commun 224:431-437
27. Kruszynska YT, Mukherjee R, Jow L, Dana S, Paterniti JR, Olefsky JM 1998 Skeletal muscle peroxisome proleferator-activated receptor-γ expression in obesity and non-insulin-dependent diabetes mellitus. J Clin Invest 101:543-548
28. Platt JL, Michael AF 1983 Retardation of fading and enhancement of intensity of immunofluorescence by p-phenylenediamine. J Histochem Cytochem 31:840-842
29. McLean IW, Nakane PK 1974 Periodate-lysine-paraformaldehyde fixative. A new fixation for immunoelectron microscopy. J Histochem Cytochem 22:1077-1083
30. James DE, Burleigh KM, Storlien LH, Bennett SP, Kraegen EW 1986 Heterogeneity of insulin action in muscle: influence of blood flow. Am J Physiol 251:E422-E430
31. Hansen PA, Gulve EA, Holloszy JO 1994 Suitability of 2-deoxyglucose for in vitro measurement of glucose transport activity in skeletal muscle. J Appl Physiol 76:979-985
32. Wallberg-Henriksson H, Zetan N, Henriksson J 1987 Reversibility of decreased insulin-stimulated glucose transport capacity in diabetic muscle with in vitro incubation. J Biol Chem 262:7665-7671
33. Stauffacher W, Renold AE 1969 Effect of insulin in vivo on diaphragm and adipose tissue of obese mice. J Biol Chem 261:3402-3407
34. Cuedet GS, Loten EG, Jeanrenaud B, Renold AE 1976 Decreased basal, non-insulin stimulated glucose uptake and metabolism by soleus skeletal muscle isolated from obese hyperglycemic (ob / ob) mice. J Clin Invest 58:1078-1088
35. Williams GD, Deldar A, Jordan WH, Gries C, Long GG, Dimarchi RD 1993 Subchronic toxicity of the thiazolidinedione, Tanabe-174, in the rat and dog. Diabetes [Suppl 1] 42:59A
36. Hofmann C, Lorenz K, Colca JR 1991 Glucose transport deficiency in diabetic animals is corrected by treatment with the oral antihyperglycemic agent Pioglitazone. Endocrinology 129:1915-1925
37. Stevenson RW, McPherson RK, Persson LM, Genereux PE, Swick AG, Spitzer J, Herbst JJ, Andrews KM, Kreutter DK, Gibbs EM 1996 The antihyperglycemic agent englitazone prevents the defect in glucose transport in rats fed a high-fat diet. Diabetes 45:60-66
38. Oakes ND, Kennedy CJ, Jenkins AB, Laybutt DR, Chisholm DJ, Kraegen EW 1994 A new antidiabetic agent, BRL 49653, reduces lipid availability and improves insulin action and glucoregulation in the rat. Diabetes 43:1203-1210
39. Weinstein SP, Holand A, O'Boyle E, Haber RS 1993 Effects of thiazolidinediones on glucocorticoid-induced insulin resistance and GLUT4 glucose transporter expression in rat skeletal muscle. Metabolism 42:1365-1369
40. Berger J, Biswas C, Hayes N, Ventre J, Wu M, Doebber TW 1996 An antidiabetic thiazolidinedione potentiates insulin stimulation of glycogen synthase in rat adipose tissue. Endocrinology 137:1984-1990
41. El-Kebbi IM, Roser S, Pollet RJ 1994 Regulation of glucose transport by Pioglitazone in cultured muscle cells. Metabolism 43:953-958
42. Bahr M, Spelleken M, Bock M, von Holtey M, Kiehn R, Eckel J 1996 Acute and chronic effects of troglitazone (CS-045) on isolated rat ventribular cardiomyocytes. Diabetologia 39:766-774
43. Wu M, Ventre J, Moller DE, Doebber T 1998 Temporal pattern of thiazolidinedione amelioration of insulin resistance in Zucker diabetic fatty rats. Diabetes [Suppl] 47:A283